Compare EXYN & COCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EXYN | COCP |
|---|---|---|
| Founded | 2014 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.2M | 21.6M |
| IPO Year | 2026 | 2011 |
| Metric | EXYN | COCP |
|---|---|---|
| Price | $2.96 | $0.96 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | ★ 1.2M | 41.6K |
| Earning Date | 11-19-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 54.65 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $12,712,091.00 |
| Revenue This Year | $29.76 | N/A |
| Revenue Next Year | $32.94 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.50 | $0.76 |
| 52 Week High | $6.98 | $2.03 |
| Indicator | EXYN | COCP |
|---|---|---|
| Relative Strength Index (RSI) | 60.00 | 28.35 |
| Support Level | $2.26 | $0.86 |
| Resistance Level | $2.98 | $1.11 |
| Average True Range (ATR) | 0.36 | 0.05 |
| MACD | 0.08 | -0.02 |
| Stochastic Oscillator | 72.73 | 13.33 |
Exyn Technologies Inc is a pioneer in fully adaptive, cognitive mission-level autonomous robotics and artificial intelligence, delivering solutions that enable safe, efficient, and scalable autonomy in complex, GPS-denied environments. Its mission is to deliver world-class autonomous robots to data-hungry industries, unlocking new insights that drive smarter decisions. The group is leveraging proprietary Level 4B autonomy software and cutting-edge aerial and ground robotic systems. It empowers industries, including mining, construction, critical infrastructure, and defense, with real-time 3D mapping, data analytics, and autonomous navigation. Its software and hardware include ExynAI, ExynAI SDK, ExynView, Nexys, Accessories, and Platforms.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). The company has one reportable and operating segment dedicated to the research and development company's novel orally administered antiviral influenza candidate. The company has pipeline products for diseases like : Influenza, Norovirus, Coronavirus, Respiratory Viruses, and Hepatitis C.